Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Mult Scler. 2022 Jan 7;28(8):1277–1285. doi: 10.1177/13524585211061861

Table 1.

Baseline characteristics by BMI at baseline--BENEFIT

Body mass index at baseline, kg per m2
<18.5 (N = 18) 18.5–<25 (N = 271) 25–<30 (N = 119) ≥30 (N = 57)
BMI, kg per m2 18.0 (17.0–18.0) 22.0 (21.0–23.0) 27.0(25.0–28.0) 32.5 (31.0–35.0)
Age at baseline, years* 29.6 (5.9) 30.1 (7.4) 31.6 (7.6) 32.7 (7.4)
Female, % 91.3 71.9 62.8 69.5
Active smokera, % 29.6 32.1 33.7 35.8
Country or region 82.3 69.6 66.2 55.7
 Central Europeb, %
 Canada, % 14.6 4.1 7.1 7.5
 Scandinavia, % 0.0 8.9 14.8 16.0
 Southern Europe, % 3.1 17.4 11.9 20.8
Time to CDMS, days 415 (141–1,497) 1,176 (351–1,804) 1,064 (342–1,805) 672 (136–1,806)
Time to MDMSd, days 191 (96.0–372.0) 194 (100–700) 214.0 (96.0–929.0) 100 (86–558)
INFß-1b treatment group, % 62.1 62.6 68.1 51.0
Multifocal onset, % 52.1 47.4 51.6 ]29.0
T2 lesion number at screening 33 (9.0–52.0) 19.0 (7.0–40.0) 17.0(8.0–33.0) 13.0 (5.0–35.0)
T2 lesion volume at screening, mm3 2,044 (1,107–8664) 1,871 (621–4,790) 1,947 (718–4,343) 1,717 (389–2,987)
Brain volume at screening, cm3 1,073 (1,056–1,097) 1,056 (1,022–1,084) 1,056 (1,019–1,082) 1,048 (1,029–1070)
EDSS at baseline 1.5(1.0–2.0) 1.5(1.0–2.0) 1.5 (1.0–2.0) 1.5(0.0–2.0)
25(OH)D at baseline, nmol/L 45.8 (38.5–61.3) 47.0 (37.6–59.0) 48.0 (37.7– 58.5) 43.9 (34–51.6)
Steroid use at baseline, % 72.9 74.6 62.3 75.6

Values are medians (interquartile ranges) or percentages and are standardized to the age distribution of the study population.

*

Value is not age adjusted

a

Active smoker defined as having all cotinine measures—baseline, months 6, 12, and 24— >25 ng/mL

b

Central Europe: Belgium, Netherlands, Germany, Austria, Switzerland, Denmark, France, Great Britain, Hungary, Czech Republic, Poland, Slovenia; Southern Europe: Spain, Portugal, Italy, Israel; Scandinavia: Finland, Norway, Sweden

d

2001 McDonald MS